ZA200402580B - Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid. - Google Patents

Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid. Download PDF

Info

Publication number: ZA200402580B
Authority: ZA; South Africa
Prior art keywords: supercritical fluid; active substance; porous support; supercritical; solvent
Prior art date: 2001-10-12

Application number

ZA200402580A

Other languages

English (en)

Inventor

Jacques Fages

Bernard Freiss

Christophe Joussot-Dubien

Letourneau Jean-Jacques Hubert

Florence Marciacq

Martial Sauceau

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-12

Filing date

2004-04-01

Publication date

2004-11-04

2004-04-01 Application filed by Pf Medicament filed Critical Pf Medicament

2004-11-04 Publication of ZA200402580B publication Critical patent/ZA200402580B/en

Links

238000000034 method Methods 0.000 title claims abstract description 125
239000013543 active substance Substances 0.000 title claims abstract description 115
239000012530 fluid Substances 0.000 title claims abstract description 94
150000001875 compounds Chemical class 0.000 title claims abstract description 32
230000003993 interaction Effects 0.000 title claims abstract description 22
238000009792 diffusion process Methods 0.000 claims abstract description 49
239000012736 aqueous medium Substances 0.000 claims abstract description 36
238000004090 dissolution Methods 0.000 claims abstract description 36
239000000203 mixture Substances 0.000 claims abstract description 33
238000005406 washing Methods 0.000 claims abstract description 29
230000003068 static effect Effects 0.000 claims abstract description 21
238000002156 mixing Methods 0.000 claims abstract description 16
239000002245 particle Substances 0.000 claims abstract description 13
230000008569 process Effects 0.000 claims description 61
229920000858 Cyclodextrin Polymers 0.000 claims description 47
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 42
239000002904 solvent Substances 0.000 claims description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
238000003756 stirring Methods 0.000 claims description 18
239000003960 organic solvent Substances 0.000 claims description 15
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 13
239000007788 liquid Substances 0.000 claims description 13
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
239000006184 cosolvent Substances 0.000 claims description 11
238000005354 coacervation Methods 0.000 claims description 10
238000004807 desolvation Methods 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 7
229960002702 piroxicam Drugs 0.000 claims description 7
239000013557 residual solvent Substances 0.000 claims description 7
-1 (S)-2’,3’,5'-trimethyl-4'- hydroxy-o-dodecylthiophenylacetanilide Chemical compound 0.000 claims description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
229940097362 cyclodextrins Drugs 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 5
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
230000008016 vaporization Effects 0.000 claims description 4
YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims description 3
150000003931 anilides Chemical class 0.000 claims description 3
239000002786 epipodophyllotoxin derivative Substances 0.000 claims description 3
239000005639 Lauric acid Substances 0.000 claims description 2
150000001298 alcohols Chemical class 0.000 claims description 2
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
239000004094 surface-active agent Substances 0.000 claims description 2
229940005605 valeric acid Drugs 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims 1
229940033355 lauric acid Drugs 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
229960002446 octanoic acid Drugs 0.000 claims 1
239000008117 stearic acid Substances 0.000 claims 1
229960004274 stearic acid Drugs 0.000 claims 1
230000002452 interceptive effect Effects 0.000 abstract 2
239000000843 powder Substances 0.000 description 52
239000000243 solution Substances 0.000 description 50
238000004458 analytical method Methods 0.000 description 35
238000000975 co-precipitation Methods 0.000 description 20
238000001556 precipitation Methods 0.000 description 19
238000002835 absorbance Methods 0.000 description 16
238000001046 rapid expansion of supercritical solution Methods 0.000 description 16
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
239000000725 suspension Substances 0.000 description 12
238000007922 dissolution test Methods 0.000 description 11
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
239000012296 anti-solvent Substances 0.000 description 9
238000003760 magnetic stirring Methods 0.000 description 9
230000000052 comparative effect Effects 0.000 description 8
238000001035 drying Methods 0.000 description 8
229920000642 polymer Polymers 0.000 description 8
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
239000012086 standard solution Substances 0.000 description 8
238000002425 crystallisation Methods 0.000 description 7
230000008025 crystallization Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
239000002609 medium Substances 0.000 description 7
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 6
239000007789 gas Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
229960000351 terfenadine Drugs 0.000 description 6
238000012360 testing method Methods 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
239000012085 test solution Substances 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 4
229960000381 omeprazole Drugs 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
229920000747 poly(lactic acid) Polymers 0.000 description 4
229960002855 simvastatin Drugs 0.000 description 4
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
238000007872 degassing Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000005843 halogen group Chemical group 0.000 description 3
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
229960000991 ketoprofen Drugs 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
238000001056 aerosol solvent extraction system Methods 0.000 description 2
238000010923 batch production Methods 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
229920006037 cross link polymer Polymers 0.000 description 2
239000013078 crystal Substances 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000005470 impregnation Methods 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002417 nutraceutical Substances 0.000 description 2
235000021436 nutraceutical agent Nutrition 0.000 description 2
239000006069 physical mixture Substances 0.000 description 2
229920001432 poly(L-lactide) Polymers 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
240000004160 Capsicum annuum Species 0.000 description 1
235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
235000014375 Curcuma Nutrition 0.000 description 1
244000164480 Curcuma aromatica Species 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
229910018830 PO3H Inorganic materials 0.000 description 1
240000005546 Piper methysticum Species 0.000 description 1
235000016787 Piper methysticum Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
229960001413 acetanilide Drugs 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000002484 anti-cholesterolemic effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
235000013614 black pepper Nutrition 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000011246 composite particle Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
150000003983 crown ethers Chemical class 0.000 description 1
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000000278 gas antisolvent technique Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
FZERHIULMFGESH-UHFFFAOYSA-N methylenecarboxanilide Natural products CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
230000009972 noncorrosive effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000008213 purified water Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Extraction Or Liquid Replacement (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Manufacturing Of Micro-Capsules (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Saccharide Compounds (AREA)
Physical Or Chemical Processes And Apparatus (AREA)

ZA200402580A 2001-10-12 2004-04-01 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid. ZA200402580B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0113178A FR2830760B1 (fr)	2001-10-12	2001-10-12	Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique

Publications (1)

Publication Number	Publication Date
ZA200402580B true ZA200402580B (en)	2004-11-04

Family

ID=8868228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200402580A ZA200402580B (en)	2001-10-12	2004-04-01	Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid.

Country Status (17)

Country	Link
US (1)	US7390411B2 (ja)
EP (1)	EP1434567B1 (ja)
JP (1)	JP4401778B2 (ja)
CN (1)	CN100396277C (ja)
AT (1)	ATE381318T1 (ja)
AU (1)	AU2002361279B2 (ja)
BR (2)	BR0213220A (ja)
CA (1)	CA2462537C (ja)
CY (1)	CY1107306T1 (ja)
DE (1)	DE60224215T2 (ja)
DK (1)	DK1434567T3 (ja)
ES (1)	ES2295446T3 (ja)
FR (1)	FR2830760B1 (ja)
MX (1)	MXPA04003300A (ja)
PT (1)	PT1434567E (ja)
WO (1)	WO2003043604A1 (ja)
ZA (1)	ZA200402580B (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2854079B1 (fr)	2003-04-25	2007-11-30	Pf Medicament	Procede de preparation de complexes moleculaires
FR2868315B1 (fr) *	2004-04-01	2006-07-14	Pierre Fabre Medicament Sa	Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
US8461133B2 (en) *	2004-04-01	2013-06-11	Pierre Fabre Medicament	Inclusion complexes containing an active substance, a cyclodextrin and an agent for interaction
FR2876914A1 (fr) *	2004-10-21	2006-04-28	Pierre Fabre Medicament Sa	Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
FR2876910B1 (fr) *	2004-10-21	2007-04-13	Pierre Fabre Medicament Sa	Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
ITSA20050008A1 (it) *	2005-03-10	2006-09-11	Univ Degli Studi Salerno	Processo per la produzione di membrane caricate con uno o piu' principi attivi
DE602006013933D1 (de) *	2006-02-10	2010-06-10	Carotech Sdn Bhd Chemor	Verfahren zur Gewinnung hochangereicherter Naturstoff-fraktionen aus Palmöl unter Verwendung von superkritischen und beinahe superkritischen Flüssigmedien
FR2944207B1 (fr) *	2009-04-09	2011-05-06	Galderma Res & Dev	Compositions comprenant au moins un complexe compose d'un derive d'acide naphtoique et d'au moins une cyclodestrine et leurs utilisations
FR2944280B1 (fr) *	2009-04-09	2012-08-03	Galderma Res & Dev	Procede de preparation de complexes moleculaires entre adapalene et des cyclodextrines
CA2833926C (en) *	2011-04-22	2015-07-21	Pepsico, Inc.	Encapsulation of extract in porous particles
EP2884523B1 (en) *	2013-12-16	2020-02-05	IMEC vzw	Method for activating a porous layer surface
CN105343893B (zh) *	2015-12-11	2018-07-20	中国药科大学	对乙酰氨基酚-2-羟丙基-β-环糊精包合物制备方法
WO2017118266A1 (en) *	2016-01-08	2017-07-13	Chen Shing-Jye	Acellular corneas, methods of producing the same and uses thereof
CN116688155A (zh) *	2023-07-20	2023-09-05	内蒙古工业大学	一种木犀草素/γ-环糊精包合物、制备方法及应用
CN118697820A (zh) *	2024-05-31	2024-09-27	广州新征程生物科技有限公司	一种治疗心脑血管病的中药及制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US189454A (en) *		1877-04-10		Improvement in paper boxes
GB2191715B (en)	1986-06-17	1990-07-25	Midrex Int Bv	Method and apparatus for dedusting and desulfurizing gases
JPH0677511B2 (ja) *	1986-12-05	1994-10-05	金印わさび株式会社	香辛成分の包接化合物の製造方法
US4822497A (en)	1987-09-22	1989-04-18	Modar, Inc.	Method for solids separation in a wet oxidation type process
DE3744329A1 (de)	1987-12-28	1989-07-06	Schwarz Pharma Gmbh	Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
FR2629735B1 (fr) *	1988-04-11	1991-03-22	Agronomique Inst Nat Rech	Procede d'extraction au dioxyde de carbone supercritique de composes volatils, et composes obtenus
GB9100643D0 (en)	1991-01-11	1991-02-27	Shaffery Michael J	Filter system
US5389263A (en)	1992-05-20	1995-02-14	Phasex Corporation	Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
DE59406065D1 (de)	1993-03-24	1998-07-02	Ciba Geigy Ag	Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
GB9313642D0 (en)	1993-07-01	1993-08-18	Glaxo Group Ltd	Method and apparatus for the formation of particles
EP0706821A1 (en)	1994-10-06	1996-04-17	Centre De Microencapsulation	Method of coating particles
FR2725990B1 (fr)	1994-10-21	1997-01-10	Pf Medicament	Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
FR2741619B1 (fr)	1995-11-28	1998-02-13	Pf Medicament	Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique
WO1997031691A1 (en)	1996-03-01	1997-09-04	The University Of Kansas	Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
FR2753639B1 (fr)	1996-09-25	1998-12-11		Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
US5766637A (en)	1996-10-08	1998-06-16	University Of Delaware	Microencapsulation process using supercritical fluids
DE19711393C1 (de)	1997-03-19	1998-08-13	Fraunhofer Ges Forschung	Verfahren zum Mikroverkapseln von Partikeln
IT1296464B1 (it)	1997-11-19	1999-06-25	Vectorpharma Int	Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
GB9810559D0 (en)	1998-05-15	1998-07-15	Bradford Particle Design Ltd	Method and apparatus for particle formation
GB9824298D0 (en)	1998-11-05	1998-12-30	Smithkline Beecham Plc	Novel process
SE9804001D0 (sv) *	1998-11-23	1998-11-23	Astra Ab	New process
US6555139B2 (en) *	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
CN1280875A (zh) *	1999-06-30	2001-01-24	刘士群	用超临界反萃剂制造微粒的方法和装置
FR2798863B1 (fr)	1999-09-27	2001-12-28	Separex Sa	Procede et installation de mise a l'etat adsorbe sur un support poreux de composes actifs contenus dans un produit
FR2799984B1 (fr)	1999-10-21	2002-05-03	Lavipharm	Procede de fractionnement d'une matiere composee de plusieurs constituants a l'aide d'un solvant a pression supercritique
FR2803538B1 (fr)	1999-12-15	2002-06-07	Separex Sa	Procede et dispositif de captage de fines particules par percolation dans un lit de granules
FR2815540B1 (fr) *	2000-10-19	2005-06-10	Separex Sa	Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
US6896905B2 (en) *	2001-02-15	2005-05-24	Rohm And Haas Company	Porous particles, their aqueous dispersions, and method of preparation
WO2002089851A1 (fr)	2001-03-06	2002-11-14	Separex (Societe Anonyme)	Procede de fabrication de complexes hote-client

2001
- 2001-10-12 FR FR0113178A patent/FR2830760B1/fr not_active Expired - Fee Related
2002
- 2002-10-11 DK DK02796803T patent/DK1434567T3/da active
- 2002-10-11 CA CA2462537A patent/CA2462537C/fr not_active Expired - Fee Related
- 2002-10-11 DE DE60224215T patent/DE60224215T2/de not_active Expired - Lifetime
- 2002-10-11 BR BR0213220-6A patent/BR0213220A/pt not_active IP Right Cessation
- 2002-10-11 AU AU2002361279A patent/AU2002361279B2/en not_active Ceased
- 2002-10-11 US US10/492,346 patent/US7390411B2/en not_active Expired - Lifetime
- 2002-10-11 AT AT02796803T patent/ATE381318T1/de active
- 2002-10-11 ES ES02796803T patent/ES2295446T3/es not_active Expired - Lifetime
- 2002-10-11 CN CNB028202031A patent/CN100396277C/zh not_active Expired - Fee Related
- 2002-10-11 WO PCT/FR2002/003474 patent/WO2003043604A1/fr active IP Right Grant
- 2002-10-11 JP JP2003545285A patent/JP4401778B2/ja not_active Expired - Fee Related
- 2002-10-11 BR BRPI0213220A patent/BRPI0213220B1/pt unknown
- 2002-10-11 EP EP02796803A patent/EP1434567B1/fr not_active Expired - Lifetime
- 2002-10-11 MX MXPA04003300A patent/MXPA04003300A/es active IP Right Grant
- 2002-10-11 PT PT02796803T patent/PT1434567E/pt unknown
2004
- 2004-04-01 ZA ZA200402580A patent/ZA200402580B/en unknown
2008
- 2008-03-13 CY CY20081100290T patent/CY1107306T1/el unknown

Also Published As

Publication number	Publication date
BRPI0213220B1 (pt)	2018-09-18
FR2830760A1 (fr)	2003-04-18
CY1107306T1 (el)	2012-11-21
AU2002361279B2 (en)	2007-02-08
US20050274671A1 (en)	2005-12-15
HK1087019A1 (zh)	2006-10-06
MXPA04003300A (es)	2004-07-23
DE60224215T2 (de)	2008-12-04
CN1713894A (zh)	2005-12-28
JP4401778B2 (ja)	2010-01-20
JP2005512621A (ja)	2005-05-12
CA2462537C (fr)	2011-06-21
PT1434567E (pt)	2008-02-08
EP1434567A1 (fr)	2004-07-07
ES2295446T3 (es)	2008-04-16
WO2003043604A1 (fr)	2003-05-30
US7390411B2 (en)	2008-06-24
DK1434567T3 (da)	2008-05-05
EP1434567B1 (fr)	2007-12-19
BR0213220A (pt)	2004-08-31
CA2462537A1 (fr)	2003-05-30
FR2830760B1 (fr)	2004-06-04
DE60224215D1 (de)	2008-01-31
AU2002361279A1 (en)	2003-06-10
ATE381318T1 (de)	2008-01-15
CN100396277C (zh)	2008-06-25

Publication	Publication Date	Title
ZA200402580B (en)	2004-11-04	Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid.
US6596315B1 (en)	2003-07-22	Method of producing drug particles
Uekama et al.	1992	Inhibitory effect of 2‐hydroxypropyl‐β‐cyclodextrin on crystal‐growth of nifedipine during storage: Superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K‐30
De Marco et al.	2008	Supercritical antisolvent micronization of cyclodextrins
JP5037936B2 (ja)	2012-10-03	分子複合体の調製のための方法
KR20060021278A (ko)	2006-03-07	고체 나노미터 의약 및 이의 제조방법
Sinisterra et al.	1999	Encapsulation and release of rhodium (II) citrate and its association complex with hydroxypropyl‐β‐cyclodextrin from biodegradable polymer microspheres
Acerbi et al.	1990	Biopharmaceutical optimisation of β-cyclodextrin inclusion compounds
WO2003030867A2 (fr)	2003-04-17	Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
CN115554415A (zh)	2023-01-03	一种环糊精结构和灰黄霉素的复合物和制备方法及其应用
HK1087019B (en)	2008-11-21	Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid
CN100391458C (zh)	2008-06-04	齐拉西酮或其盐包合物制备方法
KR101245469B1 (ko)	2013-03-25	초임계이산화탄소에 의해 퍼아세틸레이티드 사이클로덱스트린과 수용성 약물 포접체의 제조방법 및 이의 용도
HK1082430B (en)	2012-12-28	Method for the preparation of molecular complexes
Popescu et al.	0	Influence of Cyclodextrin Complexation Method on the Physical Properties and Dissolution Profile of a BCS Class II Model Drug